Paediatric asthma quality of life (PAQLQ) and their parents quality of life (PQLQ) evaluation after budesonide (Pulmicort ®) / uniphyllin treatment of asthmatic children Source: Eur Respir J 2004; 24: Suppl. 48, 164s Year: 2004
Paediatric asthma quality of life (PAQoL) score improvement in school children on combination treatment with theophillineR/beclomethasone dipropionate Source: Eur Respir J 2002; 20: Suppl. 38, 330s Year: 2002
Health related quality of life evaluation after beclomethasone dipropionate (BDP) treatment in children with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 381s Year: 2004
Paediatric asthma quality of life evaluation after Becotide® treatment of asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 145s Year: 2001
Training patients on how to use metered dose inhaler (MDI) by using the 2Tone will improve asthma quality of life (AQOL) Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008
Evaluation of quality of life (QOL) in asthma patients during 6 months formoterol therapy Source: Eur Respir J 2001; 18: Suppl. 33, 44s Year: 2001
Salmeterol/fluticasone (seretide, S/F) used as needed improves health-related quality of life in asthmatic adolescents uncontrolled with ICS receiving inhaled short-acting β2 agonists (SAB2A) Source: Eur Respir J 2004; 24: Suppl. 48, 380s Year: 2004
Achieving guideline-based asthma control: does the patient benefit? Source: Eur Respir J 2002; 20: 588-596 Year: 2002
Health related quality of life in asthmatic subjects after 3 months treatment with inhaled corticosteroids Source: International Congress 2015 – Co-existing diseases and asthma Year: 2015
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in adults and adolescents with moderate-to-severe persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Benefits of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) MDI FDC, delivered using a novel MDI co-suspension technology (GFF MDI), increase with baseline symptom severity in COPD patients (pts) Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Health-related quality of life and asthma control in patients treated with budesonide and formoterol in a single inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 46s Year: 2001
The correlation between asthma control and health status: the GOAL study Source: Eur Respir J 2007; 29: 56-62 Year: 2007
Quality of life and symptoms improvement after 6 months treatment with roflumilast 500 μg daily in a large Greek COPD cohort Source: Annual Congress 2013 –Quality of life and respiratory symptoms in primary care COPD populations Year: 2013
Health-related quality of life (HRQL) and use of formoterol in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 55s Year: 2001
Montelukast versus budesonide on quality of life in asthmatics subjects Source: Eur Respir J 2002; 20: Suppl. 38, 111s Year: 2002
Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Rhinitis quality of life (RQOL) in patients with asthma and rhinitis Source: Eur Respir J 2002; 20: Suppl. 38, 119s Year: 2002
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) 50mcg over 24 weeks in adults and adolescents with persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
NVA237 once daily improves dyspnea and health-related quality of life (HRQoL) in patients with COPD: The GLOW1 trial Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011